Anti-Shiga toxin monoclonal antibodies (Taro Pharmaceuticals)

N/A

Report date: 2022/11/25 18:10:02

Base Information

Drug NameAnti-Shiga toxin monoclonal antibodies (Taro Pharmaceuticals)
Drug Alias Namec-Stx1/c-Stx2caStx1/caStx2Anti-Stx monoclonal antibodiesShigamAbs
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionShiga toxin inhibitors
TargetsShiga toxin
Therapy Area/IndicationsBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryArgentinaChilePeru
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSunol Molecular CorpUniformed Services University Of The Health SciencesTaro Pharmaceuticals Usa Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThallion Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsBacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A